Colombia Ban of Asbestos Sets Example for US to Follow

Linda Reinstein was not surprised by the news last week that Colombia had joined the growing list of more than 60 countries to legislate a ban of asbestos. She saw it coming when she spoke on the topic at the University of Rosario in Bogota, Colombia, almost a year ago. She felt the intense passion there to prevent more innocent lives being lost to asbestos-related diseases such as mesothelioma. “It was another experience where the heartache, grief and anger of asbestos victims all came together and turned into action to facilitate change,” Reinstein, president and CEO of the Asbestos Disease Awareness Organization, told The Mesothelioma Center at Asbestos.com. “In Colombia, they have crossed the finish line.” Lawmakers in Colombia voted unanimously to ban the production, use and sale of asbestos products, beginning in 2021. The victory in Colombia followed seven earlier legislative defeats over the previous 12 years. “History was made,” said Silvia Gomez, director of Greenpeace Colombia, which lobbied for the ban for many years. “It was an unprecedented victory for the health of the country. It also is a tribute to the victims of asbestos and the tireless and exciting struggle of their relatives.” The U.S. remains one of a few industrialized nations without a comprehensive ban like the one passed in Colombia. Ban Includes a Five-Year Transition Period Colombia’s ban is only the second time a major asbestos-producing count...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractActivated cap-dependent translation promotes cancer by stimulating translation of mRNAs encoding malignancy-promoting proteins. The nucleoside monophosphate Protide, 4Ei-10, undergoes intracellular uptake and conversion by Hint1 to form 7-Cl-Ph-Ethyl-GMP. 7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap. The effects of inhibiting translation initiation by disruption of the eIF4F complex with 4Ei-10 were examined in malignant mesothelioma (MM). In a cell-free assay system, formation of the eIF4F complex was disab...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Asbestosis | Brazil Health | Cancer | Cancer & Oncology | Colombia Health | Environmental Health | International Medicine & Public Health | Legislation | Mesothelioma | Politics | Schools | USA Health